Arcus Biosciences (RCUS) Tops Q4 EPS by 22c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($0.93), $0.22 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $34 million versus the consensus estimate of $22.59 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded